DataArt in the News
In a bylined article for iGaming Business, Russell Karp, VP of Media and Entertainment at DataArt, looks at the halt of the gambling industry as an opportunity to re-evaluate, enhance and future-proof underlying technology and execute strategic initiatives.
In InsurTech Insights, DataArt’s experts, Denis Baranov and Peter Rakowsky, discuss how insurance companies can benefit from outsourcing.
Standing on the Shoulders of Giants: The Art & Science of Machine Learning & AI for Drug Discovery & Repurposing
In Pharmaboardroom, Daniel Piekarz, SVP Healthcare and Life Sciences at DataArt, explores how machine learning and artificial intelligence can play into drug repurposing, potentially providing solutions to the most pressing healthcare concerns of today, including the COVID-19 pandemic.
In a bylined article for iGaming Business, Russell Karp, VP of Media and Entertainment at DataArt, discusses the hurdles faced by the GB Gambling Commission with its responsible gambling initiative and shares his ideas on possible solutions.
In HCPLive, Daniel Piekarz, SVP of Healthcare & Life Sciences at DataArt, debates whether the COVID-19- related clinical trial standstill will drive the industry towards virtual trials.
In conversation with experts in the field, How-To Geek explores various aspects of contract tracing and its impact on managing infectious diseases. Daniel Piekarz, SVP Healthcare and Life Sciences at DataArt, shares his thoughts on the concept, its uses, and its effectiveness.
Automative speaks with industry experts, including Iliya Aristov, Head of Logistics at DataArt, about the state of autonomous vehicles. Aristov comments on why the global automotive sector is still falling short of Level 3 autonomy.
Tabb Forum publishes DataArt’s discussion of key trends, including robotic process automation (RPA), big data analytics, and artificial intelligence (AI), that will drive the technological transformations in financial services in 2020.
In Manufacturing Chemist, Egor Kobelev, VP of Healthcare and Life Sciences at DataArt, shares some of the ways artificial intelligence (AI) and machine learning technologies help identify new molecules and validate new drugs faster and more efficiently.